Trial Profile
A Phase Ib/II Study of Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in Participants With Previously Treated Metastatic and/ or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 18 Mar 2022
Price :
$35
*
At a glance
- Drugs LMB 100 (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 16 Feb 2022 Status changed from active, no longer recruiting to completed.
- 31 May 2020 Results (n=15) assesing the safety and tolerability of administering LMB-100 in a long infusion format over 24-48 hours alone or with nab-paclitaxel chemotherapy in patients with mesothelin-expressing solid tumors, presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 19 Feb 2020 Planned End Date changed from 1 Jan 2021 to 31 Jan 2022.